NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Forecast, Price & News

$7.28

-0.18 (-2.41%)

(As of 09/22/2023 ET)

Compare

Today's Range: $6.95
▼
$7.50
50-Day Range: $6.66
▼
$10.64
52-Week Range: $6.45
▼
$28.20

Volume: 287,574 shs
Average Volume: 228,525 shs
Market Capitalization: $424.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.60

IGM Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 224.2% Upside
$23.60 Price Target
Short Interest: Bearish
28.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.08
Upright™ Environmental Score
News Sentiment: 0.21
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$931,850 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($5.16) to ($4.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

159th out of 963 stocks

Pharmaceutical Preparations Industry

57th out of 458 stocks

4.3

Analyst's Opinion

Consensus Rating
IGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.60, IGM Biosciences has a forecasted upside of 224.2% from its current price of $7.28.
Amount of Analyst Coverage
IGM Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
28.16% of the float of IGM Biosciences has been sold short.
Short Interest Ratio / Days to Cover
IGM Biosciences has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.
Change versus previous month
Short interest in IGM Biosciences has recently increased by 2.92%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
IGM Biosciences does not currently pay a dividend.
Dividend Growth
IGM Biosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for IGM Biosciences is -1.08.

2.3

News and Social Media Coverage

News Sentiment
IGM Biosciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for IGM Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for IGMS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IGM Biosciences insiders have bought 10,468.79% more of their company's stock than they have sold. Specifically, they have bought $931,850.00 in company stock and sold $8,817.00 in company stock.
Percentage Held by Insiders
56.91% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.21% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for IGM Biosciences are expected to grow in the coming year, from ($5.16) to ($4.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IGM Biosciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IGM Biosciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IGM Biosciences has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IGM Biosciences (NASDAQ:IGMS) Stock

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Price History

30 days | 90 days | 365 days | Advanced Chart

IGMS Stock News Headlines

September 20, 2023 | finance.yahoo.com

Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?

September 7, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), IGM Biosciences (IGMS) and Adverum Biotechnologies (ADVM)

September 24, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 7, 2023 | msn.com

Truist Securities Reiterates IGM Biosciences (IGMS) Buy Recommendation

September 6, 2023 | finance.yahoo.com

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 17, 2023 | msn.com

RBC Capital Reiterates IGM Biosciences (IGMS) Sector Perform Recommendation

August 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Intuitive Surgical (ISRG)

August 11, 2023 | finance.yahoo.com

Down More Than 50%: These 2 ‘Strong Buy’ Stocks Are Too Cheap to Ignore

September 24, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 8, 2023 | msn.com

Morgan Stanley Maintains IGM Biosciences (IGMS) Equal-Weight Recommendation

August 8, 2023 | msn.com

Needham Downgrades IGM Biosciences (IGMS)

August 4, 2023 | finanznachrichten.de

IGM Biosciences, Inc.: IGM Biosciences Announces Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

IGM Biosciences Announces Second Quarter 2023 Financial Results

July 3, 2023 | finance.yahoo.com

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

June 30, 2023 | finance.yahoo.com

While hedge funds own 27% of IGM Biosciences, Inc. (NASDAQ:IGMS), individual investors are its largest shareholders with 28% ownership

June 23, 2023 | finance.yahoo.com

Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?

June 22, 2023 | markets.businessinsider.com

Why IGM Biosciences (IGMS) Stock Is Trading Higher

June 22, 2023 | finance.yahoo.com

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

June 21, 2023 | msn.com

IGM Biosciences plans for $100M stock offering and concurrent private placement

June 21, 2023 | finance.yahoo.com

IGM Announces Proposed Public Offering and Concurrent Private Placement

June 7, 2023 | markets.businessinsider.com

Robert W. Baird Sticks to Its Buy Rating for IGM Biosciences (IGMS)

June 6, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Legend Biotech (LEGN), Shattuck Labs (STTK)

June 6, 2023 | msn.com

HC Wainwright & Co. Reiterates IGM Biosciences (IGMS) Buy Recommendation

June 5, 2023 | msn.com

Wedbush Reiterates IGM Biosciences (IGMS) Outperform Recommendation

June 1, 2023 | finance.yahoo.com

IGM Biosciences to Present at the Jefferies Healthcare Conference

May 31, 2023 | finance.yahoo.com

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

May 30, 2023 | finance.yahoo.com

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

See More Headlines

Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IGMS Company Calendar

Last Earnings: 8/03/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IGMS
CUSIP: N/A
CIK: 1496323
Web: igmbio.com
Phone: 650-965-7873
Fax: N/A
Employees: 289
Year Founded: 2010

Price Target and Rating

Average Stock Price Forecast: $23.60
High Stock Price Forecast: $55.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +224.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-221,100,000.00
Net Margins: -14,007.47%
Pretax Margin: -13,995.76%
Return on Equity: -84.18%
Return on Assets: -46.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.07
Quick Ratio: 9.07

Sales & Book Value

Annual Sales: $1.07 million
Price / Sales: 397.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.67 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 58,370,000
Free Float: 25,150,000
Market Cap: $424.93 million
Optionable: Not Optionable
Beta: -0.24

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Fred M. Schwarzer J.D. (Age 70)
CEO, Pres & Director
Comp: $977.66k

Dr. Bruce A. Keyt (Age 70)
Chief Scientific Officer
Comp: $692.95k

Dr. Chris H. Takimoto FACP (Age 64)
M.D., Ph.D., Chief Medical Officer
Comp: $684.95k

Mr. Misbah Tahir (Age 48)
Chief Financial Officer

Mr. TS Harigopal
Sr. VP of Group Operations

Mr. Steven Weber (Age 47)
Sr. VP, Corp. Controller & Principal Accounting Officer

Mr. Paul C. Graffagnino
VP of Legal Affairs

Ms. Suzette Tauber (Age 59)
Chief HR Officer

Dr. Angus M. Sinclair Ph.D.
Sr. VP of Immuno-Oncology

Dr. Lisa L. Decker Ph.D. (Age 54)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IGMS Stock - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings or view top-rated stocks.
What is IGM Biosciences' stock price forecast for 2023?: 8 brokerages have issued 1-year price objectives for IGM Biosciences' shares. Their IGMS share price forecasts range from $11.00 to $55.00. On average, they anticipate the company's stock price to reach $23.60 in the next twelve months. This suggests a possible upside of 224.2% from the stock's current price.
View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts.
How have IGMS shares performed in 2023?: IGM Biosciences' stock was trading at $17.01 at the beginning of the year. Since then, IGMS stock has decreased by 57.2% and is now trading at $7.28.
View the best growth stocks for 2023 here.
When is IGM Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IGMS earnings forecast.
How were IGM Biosciences' earnings last quarter?: IGM Biosciences, Inc. (NASDAQ:IGMS) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.40) by $0.03. The business earned $0.45 million during the quarter, compared to analysts' expectations of $0.80 million. IGM Biosciences had a negative trailing twelve-month return on equity of 84.18% and a negative net margin of 14,007.47%. The company's revenue for the quarter was up 22.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS.
What ETFs hold IGM Biosciences' stock?: ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of IGM Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?: (IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.
What is IGM Biosciences' stock symbol?: IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."
Who are IGM Biosciences' major shareholders?: IGM Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Artal Group S.A. (5.85%), RA Capital Management L.P. (1.61%), BlackRock Inc. (1.99%), Goldman Sachs Group Inc. (1.15%), Great Point Partners LLC (0.86%) and State Street Corp (0.45%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg and Misbah Tahir.
View institutional ownership trends.
How do I buy shares of IGM Biosciences?: Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IGM Biosciences' stock price today?: One share of IGMS stock can currently be purchased for approximately $7.28.
How much money does IGM Biosciences make?: IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $424.93 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis.
How many employees does IGM Biosciences have?: The company employs 289 workers across the globe.
How can I contact IGM Biosciences?: IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.

This page (NASDAQ:IGMS) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial